Advertisement

Contemporary Systemic Therapies in Urothelial Carcinoma

Published:January 19, 2023DOI:https://doi.org/10.1016/j.urology.2023.01.007

      Abstract

      Prior to the past decade, systemic therapy options for muscle-invasive bladder cancer (MIBC) or locally advanced/metastatic urothelial carcinoma (la/mUC) were dismal for cisplatin-ineligible patients and after progression on chemotherapy. Although the bulk of available evidence for novel systemic therapies exists in the la/mUC setting, emerging data suggests an important role in the neoadjuvant and adjuvant spaces as well. In this narrative review, we examine the application of contemporary systemic therapies to urothelial carcinoma (UC) including immune checkpoint inhibitors (ICIs), antibody-drug conjugates (ADCs), and targeted therapies. We additionally acknowledge the potential of combination therapies to further potentiate a durable synergistic response.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A.
        Cancer Statistics, 2021.
        CA Cancer J Clin. 2021; 71: 7-33https://doi.org/10.3322/caac.21654
      1. Flaig TW, Spiess PE, Chair V, et al. NCCN Guidelines Version 2.2022 Bladder Cancer.; 2022. https://www.nccn.org/home/member-

        • Galsky MD
        • Hahn NM
        • Rosenberg J
        • et al.
        Treatment of patients with metastatic urothelial cancer “Unfit” for cisplatin-based chemotherapy.
        Journal of Clinical Oncology. 2011; 29: 2432-2438https://doi.org/10.1200/JCO.2011.34.8433
        • Jenkins RW
        • Barbie DA
        • Flaherty KT.
        Mechanisms of resistance to immune checkpoint inhibitors.
        Br J Cancer. 2018; 118: 9-16https://doi.org/10.1038/bjc.2017.434
        • Buchbinder EI
        • Desai A.
        CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition.
        American Journal of Clinical Oncology: Cancer Clinical Trials. 2016; 39: 98-106https://doi.org/10.1097/COC.0000000000000239
        • Vale CL.
        Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data.
        Eur Urol. 2005; 48: 202-206https://doi.org/10.1016/j.eururo.2005.04.006
        • Grossman HB
        • Natale RB
        • Tangen CM
        • et al.
        Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
        N Engl J Med. 2003; 349: 859-866https://doi.org/10.1056/NEJMoa022148
        • Necchi A
        • Anichini A
        • Raggi D
        • et al.
        Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study.
        Journal of Clinical Oncology. 2018; 36: 3353-3360https://doi.org/10.1200/JCO.18.01148
        • Necchi A
        • Raggi D
        • Gallina A
        • et al.
        Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.
        Eur Urol. 2020; 77: 439-446https://doi.org/10.1016/j.eururo.2019.10.026
        • Galsky MD
        • Hoimes CJ
        • Necchi A
        • et al.
        Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303.
        Future Oncology. 2021; 17: 3137-3150https://doi.org/10.2217/fon-2021-0273
        • Carthon BC
        • Wolchok JD
        • Yuan J
        • et al.
        Preoperative CTLA-4 blockade: Tolerability and immune monitoring in the setting of a presurgical clinical trial.
        Clinical Cancer Research. 2010; 16: 2861-2871https://doi.org/10.1158/1078-0432.CCR-10-0569
        • Hoimes CJ
        • Adra N
        • Fleming MT
        • et al.
        Phase Ib/II Neoadjuvant (N-) Pembrolizumab (P) and Chemotherapy for Locally Advanced Urothelial Cancer (laUC): Final Results from the Cisplatin (C)-eligible Cohort of HCRN GU14-188.
        J Clin Oncol. 2020; 38 (5047-5047)
        • Gupta S
        • Sonpavde G
        • Weight CJ
        • et al.
        Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.
        Journal of Clinical Oncology. 2020; 38 (439-439)https://doi.org/10.1200/JCO.2020.38.6_suppl.439
        • Gupta S
        • Gibb E
        • Sonpavde GP
        • et al.
        Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.
        Journal of Clinical Oncology. 2022; 40 (528-528)https://doi.org/10.1200/JCO.2022.40.6_suppl.528
        • Szabados B
        • Kockx M
        • Assaf ZJ
        • et al.
        Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
        Eur Urol. August 1, 2022; (Published online)https://doi.org/10.1016/j.eururo.2022.04.013
        • Yuk HD
        • Jeong CW
        • Kwak C
        • Kim H
        • Moon KC
        • Ku JH.
        Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: A study protocol for an open-label, two-cohort, phase II trial.
        BMJ Open. 2020; 10https://doi.org/10.1136/bmjopen-2019-035530
        • Natesan DV
        • Zhang L
        • Oh DY
        • et al.
        Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423).
        Journal of Clinical Oncology. 2021; 39 (e16510-e16510)https://doi.org/10.1200/JCO.2021.39.15_suppl.e16510
        • Powles T
        • Meeks JJ
        • Galsky MD
        • et al.
        A phase III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA).
        Journal of Clinical Oncology. 2021; 39 (TPS505-TPS505)https://doi.org/10.1200/JCO.2021.39.6_suppl.TPS505
        • Martinez Chanza N
        • Soukane L
        • Barthelemy P
        • et al.
        Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
        BMC Cancer. 2021; 21https://doi.org/10.1186/s12885-021-08990-3
        • van Dijk N
        • Gil-Jimenez A
        • Silina K
        • et al.
        Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.
        Nat Med. 2020; 26: 1839-1844https://doi.org/10.1038/s41591-020-1085-z
        • Gao J
        • Navai N
        • Alhalabi O
        • et al.
        Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
        Nat Med. 2020; 26: 1845-1851https://doi.org/10.1038/s41591-020-1086-y
        • Thibault C
        • Elaidi R
        • Vano YA
        • et al.
        Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
        Bull Cancer. 2020; 107: eS8-eS15https://doi.org/10.1016/S0007-4551(20)30281-2
        • Sonpavde G
        • Necchi A
        • Gupta S
        • et al.
        ENERGIZE: A Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
        Future Oncology. 2019; 16: 4359-4368https://doi.org/10.2217/fon-2019-0611
        • de Ruiter BM
        • van Hattum JW
        • de Reijke TM
        • Oddens JR
        • Hulshof MCCM
        • Bins AD.
        Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).
        Journal of Clinical Oncology. 2021; 39 (4531-4531)https://doi.org/10.1200/JCO.2021.39.15_suppl.4531
        • Bajorin DF
        • Witjes JA
        • Gschwend JE
        • et al.
        Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
        New England Journal of Medicine. 2021; 384: 2102-2114https://doi.org/10.1056/nejmoa2034442
      2. U.S. Food & Drug Administration. FDA approves nivolumab for adjuvant treatment of urothelial carcinoma. FDA News Release. Published August 19, 2021. Accessed August 18, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-adjuvant-treatment-urothelial-carcinoma#:∼:text=FDA%20approves%20nivolumab%20for%20adjuvant%20treatment%20of%20urothelial%20carcinoma,-Share&text=On%20August%2019%2C%202021%2C%20the,recurrence%20after%20undergoing%20radical%20resection.

        • Bellmunt J
        • Hussain M
        • Gschwend JE
        • et al.
        Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2021; 22: 525-537https://doi.org/10.1016/S1470-2045(21)00004-8
        • Powles T
        • Assaf ZJ
        • Davarpanah N
        • et al.
        ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
        Nature. 2021; 595: 432-437https://doi.org/10.1038/s41586-021-03642-9
      3. Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer (AMBASSADOR).
        ClinicalTrials.gov Identifier:NCT03244384. 2017; (Published onlineAccessed August 18, 2022)
      4. U.S. Food & Drug Administration. Nivolumab for Treatment of Urothelial Carcinoma. Published February 2, 2017. Accessed September 18, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/nivolumab-treatment-urothelial-carcinoma

      5. Pembrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma. FDA.

        • Genentech Press Release
        FDA Grants Genentech's Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer.
        Genentech. April 17, 2017; (PublishedAccessed August 18, 2022)
      6. Galsky MD, Ángel J, Arija A, et al. Atezolizumab with or without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. Vol 395.; 2020. www.thelancet.com

        • Powles T
        • van der Heijden MS
        • Castellano D
        • et al.
        Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
        Lancet Oncol. 2020; 21: 1574-1588https://doi.org/10.1016/S1470-2045(20)30541-6
        • Martini A
        • Raggi D
        • Fallara G
        • et al.
        Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis.
        Cancer Treat Rev. 2022; 104102360https://doi.org/10.1016/j.ctrv.2022.102360
      7. Balar A v., Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;389(10064):67-76. doi:10.1016/S0140-6736(16)32455-2

        • U.S. Food & Drug Administration
        FDA approves new, targeted treatment for bladder cancer.
        FDA News Release. May 16, 2016; (PublishedAccessed August 18, 2022)
        • Rosenberg JE
        • Hoffman-Censits J
        • Powles T
        • et al.
        Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial.
        The Lancet. 2016; 387: 1909-1920https://doi.org/10.1016/S0140-6736(16)00561-4
        • Necchi A
        • Joseph RW
        • Loriot Y
        • et al.
        Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study.
        Annals of Oncology. 2017; 28: 3044-3050https://doi.org/10.1093/annonc/mdx518
        • Powles T
        • Durán I
        • van der Heijden MS
        • et al.
        Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
        The Lancet. 2018; 391: 748-757https://doi.org/10.1016/S0140-6736(17)33297-X
        • van der Heijden MS
        • Loriot Y
        • Durán I
        • et al.
        Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
        Eur Urol. 2021; 80: 7-11https://doi.org/10.1016/j.eururo.2021.03.024
        • Hopkins AM
        • Kichenadasse G
        • Karapetis CS
        • Rowland A
        • Sorich MJ.
        Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab.
        Clinical Cancer Research. 2020; 26: 5487-5493https://doi.org/10.1158/1078-0432.CCR-20-1876
        • Hopkins AM
        • Kichenadasse G
        • Karapetis CS
        • Rowland A
        • Sorich MJ.
        Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
        Eur Urol. 2020; 78: 540-543https://doi.org/10.1016/j.eururo.2020.06.061
        • Balar AV
        • Castellano D
        • O'Donnell PH
        • et al.
        First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
        Lancet Oncol. 2017; 18: 1483-1492https://doi.org/10.1016/S1470-2045(17)30616-2
      8. Vuky J, Balar Av, Castellano D, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Vol 38.; 2020. https://doi.org/10.

        • Grivas P
        • Plimack ER
        • Balar A v.
        • et al.
        Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
        Eur Urol Oncol. 2020; 3: 351-359https://doi.org/10.1016/j.euo.2020.02.009
        • Merseburger AS
        • Castellano D
        • Powles T
        • et al.
        Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
        J Urol. 2021; 206: 240-251https://doi.org/10.1097/JU.0000000000001768
        • Powles T
        • Csőszi T
        • Özgüroğlu M
        • et al.
        Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2021; 22: 931-945https://doi.org/10.1016/S1470-2045(21)00152-2
        • Bellmunt J
        • de Wit R
        • Vaughn DJ
        • et al.
        Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
        New England Journal of Medicine. 2017; 376: 1015-1026https://doi.org/10.1056/nejmoa1613683
        • Minato A
        • Furubayashi N
        • Harada M
        • et al.
        Efficacy of Pembrolizumab in Patients With Variant Urothelial Carcinoma: A Multicenter Retrospective Study.
        Clin Genitourin Cancer. 2022; (Published online)https://doi.org/10.1016/j.clgc.2022.05.001